NCT03637517 - Malaria: Relative Bioavailability and Food Effect of DSM265 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2018

Primary Completion Date

November 19, 2018

Study Completion Date

November 19, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

DSM265-TPGS 34% SDD, 400 mg fasted

New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.

DRUG

DSM265-TPGS 34% SDD, 400 mg fed

New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.

DRUG

DSM265 25% SDD, 400 mg fasted

Reference formulation used in early clinical trials.

Trial Locations (1)

AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake